Posted on

SDT Holdings Improve Transparency with Information & Disclosure Statement Filing

MONTREAL, July 25, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE  —  SDT Holdings, Inc. / Wuhan General Group (China), Inc. (OTC PINK:WUHN) (the “Company”), a Montreal-based industrial technology holding company serving various industries through their four subsidiaries, filed its Information and Disclosure Statement with OTC Markets.

The Company’s Information and Disclosure Statement includes financial statements for the years ended 2016 and 2017, as well as first quarter 2018. The Company believes it has now filed the necessary documentation with OTC Market to achieve Current Pink status.

The Company has also filed Articles of Amendment with Nevada Secretary of State changing the Company’s name from “Wuhan General Group (China), Inc.” to “SDT Holdings, Inc.” The Company has begun work with FINRA to implement the name change and is seeking to change its ticker symbol. Potential options for the new ticker symbol include “SDTH” and “SDTG” which are under consideration as well as others if these they are unavailable.

“We are very happy to have made our financials available on the OTC Markets website,” commented Ramy Kamaneh, CEO of WUHN. “We are extremely grateful for all the hard work that our financial and legal teams have put in place to lead us today. We do not control the outcome of these efforts, which took more time and capital than originally planned, but we believe that improving transparency for our investors is an important milestone, and with all these changes undertaken, we hope to continue to grow our business and create strong shareholder value.”

About

SDT Holdings, Inc. is a Montreal-based industrial technology holding company that focuses on the development, production and commercialization of its four subsidiaries, specialized in these areas: mining electrification, cryptocurrencies / blockchain, industrial batteries, internet of things and artificial intelligence for the industrial market. Dedicated to supplying quality, innovative technologies and battery solutions.

Contact: Bruce Haase Public Relations
Phone: (514) 928-7368 ext. 6
E-mail: info@sdtholdings.com
Website: www.sdtholdings.com

Forward-Looking Statements

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Source: Wuhan General Group (China), Inc.

Posted on

Statement from Vireo Health on Department of Health’s Decision to Improve Patient Access to Medical Marijuana for New Yorkers Prescribed Opioids

The following statement regarding New York State’s plan to allow medical cannabis to be used as an alternative to prescription opioids can be attributed to Dr. Stephen Dahmer, Chief Medical Officer of Vireo Health, one of only 10 organizations licensed in the state to grow, cultivate, manufacture and sell medical cannabis:

“Today’s announcement made by Department of Health Commissioner Dr. Howard Zucker is an important step towards potentially helping thousands of New Yorkers that rely on opioid-based medications to treat their pain. We are fully prepared to work collaboratively with the Department to improve medical cannabis access and support for more New Yorkers who can benefit from these medicines.”

###

 

About Vireo Health of New York

Vireo Health of New York is a physician-led company dedicated to providing best-in-class cannabis-based medications and compassionate care. The Company is a proven leader in the field of medical marijuana. In December 2015, Vireo’s products became the first to be certified Kosher by the Orthodox Union. In addition to brick-and-mortar dispensary locations, Vireo launched the first medical marijuana home delivery service in the New York City area, now available throughout New York City, Westchester, Rockland, Nassau and parts of Suffolk County. For more information, visit https://vireohealth.com/ny/.

Posted on

SDT Holdings, Inc. Provides Corporate Update

MONTREAL, June 13, 2018 (GLOBE NEWSWIRE) — SDT Holdings, Inc. / Wuhan General Group (China), Inc. (OTC PINK:WUHN) (the “Company”), a Montreal-based industrial technology holding company serving various industries through their four subsidiaries, announces major developments.

”Launching a business like SDT and going public is both exciting and overwhelming at the same time,” said CEO, Ramy Kamaneh. “We’ve been busy working toward achieving multiple milestones in the first half of 2018 to build the necessary foundation and structure required for long-term growth and shareholder value improvement.”

Launched New Corporate Website

The Company is proud to announce the launch of its corporate website, an important milestone that directly reflects the Company’s vision and will serve a key role in communicating with investors and customers.

Please visit the company’s new corporate website to learn more:  https://sdtholdings.com/

Team Members Additions

Gerald Bernstein has been appointed Chief Financial Officer of SDT Holdings.

”We’re pleased to welcome Gerald to the team,” said CEO, Ramy Kamaneh. “His financial expertise and knowledge of the public space will be an important asset to the company. By quickly integrating with the company, Gerald will help fast-track our process of becoming a fully reporting company in the coming weeks.”

Patents

The company has engaged Anglehart et al., an IP-focused law firm, for pending and future intellectual property applications. Progress is already being made in this arena and the Company expects intellectual property to add significant value to its balance sheet.

About 

SDT Holdings, Inc. is a Montreal-based industrial technology holding company that focuses on the development, production and commercialization of its four subsidiaries, specializing in these areas: mining electrification, cryptocurrencies / blockchain, industrial batteries, internet of things and artificial intelligence for the industrial market. Dedicated to supplying quality, innovative technologies and battery solutions, SDT Holdings services the transport, mining, agricultural, industrial and earthmoving industries.

Forward-Looking Statements

This press release contains forward-looking statements. Such statements include statements regarding our expectations, hopes, beliefs or intentions regarding the future, including but not limited to statements regarding our market, strategy, competition, development plans (including acquisitions and expansion), financing, revenues, operations, and compliance with applicable laws. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. Factors that could cause actual results to differ materially from such forward-looking statements include the risks described in greater detail in the following paragraphs. All forward-looking statements in this document are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligation to update any forward-looking statement except where applicable law requires us to update these statements. Market data used throughout this prospectus is based on published third party reports or the good faith estimates of management, which estimates are based upon their review of internal surveys, independent industry publications and other publicly available information.

Source: Wuhan General Group (China), Inc.
Contact: info@sdtholdings.com

Posted on

SDT Holdings, Inc. to Present at RedChip’s Global Online Growth Conference

MONTREAL, May 01, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — SDT Holdings, Inc. / Wuhan General Group (China), Inc. (USOTC:WUHN), announced today that it is scheduled to present at RedChip’s Global Online Growth Conference on Wednesday, May 2nd, at 1:00pm ET. The presentation can be viewed at www.RedChip.com. A live Q&A session will follow the investor presentation.

RedChip’s Global Online Growth Conference brings together investors and executives of leading small-cap companies, representing a broad spectrum within many sectors. More than 10,000 investors attend RedChip’s microcap conference series each year.

No registration is required to participate in the conference. Start times are subject to change.

About 

SDT Holdings, Inc. is a Montreal-based industrial technology holding company that focuses on the development, production and commercialization of its four subsidiaries, specializing in these areas: mining electrification, cryptocurrencies / blockchain, industrial batteries, internet of things and artificial intelligence for the industrial market. Dedicated to supplying quality, innovative technologies and battery solutions, SDT Holdings services the transport, mining, agricultural, industrial and earthmoving industries.

Forward-Looking Statements

This press release contains forward-looking statements. Such statements include statements regarding our expectations, hopes, beliefs or intentions regarding the future, including but not limited to statements regarding our market, strategy, competition, development plans (including acquisitions and expansion), financing, revenues, operations, and compliance with applicable laws. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. Factors that could cause actual results to differ materially from such forward-looking statements include the risks described in greater detail in the following paragraphs. All forward-looking statements in this document are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligation to update any forward-looking statement except where applicable law requires us to update these statements. Market data used throughout this prospectus is based on published third party reports or the good faith estimates of management, which estimates are based upon their review of internal surveys, independent industry publications and other publicly available information.

Contact:

Bruce Haase
RedChip Companies
407-644-4256, ext. 131
bruce@redchip.com

Posted on

ABBVIE RECEIVES POSITIVE RECOMMENDATION FROM THE PAN- CANADIAN ONCOLOGY DRUG REVIEW FOR VENCLEXTATM – AN ORAL THERAPY FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

  • pCODR conditionally recommends the reimbursement of VENCLEXTA for the treatment of patients with CLL who have received at least one prior therapy and who have failed a BCRii
  • VENCLEXTA is the first and only approved BCL-2 inhibitor in Canada
  • A need exists for CLL patients who have failed novel oral therapiesii

 

Montreal, QC, March 6, 2018 – AbbVie, a global research and development-based biopharmaceutical company, today announced that the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee conditionally recommends the reimbursement of VENCLEXTATM for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a BCRi. This recommendation is a positive step towards patients living with CLL accessing a medication that serves an unmet medical need.

 

VENCLEXTA is a first-in-class, oral, once-daily medicine. It selectively inhibits the BCL-2 protein, which is responsible for helping cancer cells survive in the blood.

 

“Lymphoma Canada understands the high relapse rate of CLL that necessitates a variety of treatment options. The positive recommendation of VENCLEXTA provides Canadians living with CLL with hope for the future, which is an important determinant as one battles this disease,” says Robin Markowitz, CEO, Lymphoma Canada. “Lymphoma Canada is confident that the pan-Canadian Oncology Drug Review

Expert Review Committee’s decision to recommend VENCLEXTA for reimbursement will provide patients with comfort to know that they have additional treatment options.”

 

CLL, which is typically a slow-progressing cancer of the bone marrow and bloodiii, is one of the most common types of leukemia in adults. In Canada, CLL accounts for approximately 2,200 newly diagnosed cases of leukemia each year and is responsible for more than 600 deaths a year.iv The 17p deletion is a genetic mutation that is found in 3 to 10 percent of people with previously untreated CLL and up to 50 percent of relapsed or refractory cases.v Despite the development of new therapies for relapse/refractory (R/R) CLL, there remains a need for salvage therapies for patients that have failed treatment because they have relapsed, are refractory or simply intolerant or unsuitable to the toxicity profile of these newer agents. ii

 

“The first thing I understood during my initial consultation with my Hematologist about my leukaemia is that it was chronic. Since my diagnosis in 2010, I have relapsed twice, but I have always been fortunate that the right treatment was available to me at the right time,” explains Mark Silverstein of Aurora, ON. “This last relapse was no different, and the treatment I had been excited about for several years was made available only a couple of months prior to my second relapse. Now with VENCLEXTA, Canadians

 

living with CLL have another treatment option. I have chosen my own way over the last seven years – by educating myself on my disease, maintaining a healthy partnership with my Hematologist, by removing fear from my choices, and finally to consistently remain intellectually, emotionally, and spiritually open to a journey with no assurances how it will all turn out.”

 

VENCLEXTA previously received a Notice of Compliance with Conditions (NOC/c) by Health Canada on September 27, 2016. The therapy has been approved for previously treated chronic lymphocytic leukemia (CLL) patients, who have either a genetic mutation, known as 17p deletion, or no other available treatment options. Under NOC/c policy, AbbVie will provide Health Canada with data from additional studies to confirm the clinical benefit of VENCLEXTA.vi

 

“For people living with CLL, the goal of treatment is to delay progression of the disease and improve quality of life. Therefore, providing Canadians access to an approved treatment option is essential. The entire team at AbbVie Canada applauds and celebrates the pan-Canadian Oncology Drug Review recommendation for VENCLEXTA,” said Stéphane Lassignardie, General Manager of Abbvie Canada. “This recommendation reinforces AbbVie’s growing position in hematologic oncology.”

 

VENCLEXTA continues to be investigated in CLL and other hematological diseases.

 

VENCLEXTA is being developed by AbbVie and Genentech, a member of the Roche Group. It is jointly commercialized by the companies in the U.S. and by AbbVie outside of the U.S.

 

About AbbVie Care

Canadians prescribed VENCLEXTA will have the opportunity to be enrolled in AbbVie Care, AbbVie’s signature care program. The program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment and beyond.

 

About AbbVie

AbbVie is a global, research and development-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

 

-30-

Media Inquiries:

Muriel Haraoui muriel.haraoui@abbvie.com 514.717.3764

 

 

i pCODR Expert Review Committee (pERC) Final Recommendation https://www.cadth.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_fn_rec.pdf

iiJain P. et al. Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib.

Cancer. 2017 Jun 15;123(12):2268-2273.

iii Lymphoma Canada. Chronic lymphocytic leukemia. Available at http://www.lymphoma.ca/lymphoma/lymphoma-101/types-lymphoma/cll

iv Canadian Cancer Statistics, 2015 http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic- lymphocytic-cll/statistics/?region=on

v Schnaiter A. et al. 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.

Hematol Oncol Clin N Am. 2013;27:289–301.

vi VENCLEXTA product monograph, AbbVie Corporation, September 27, 2016

Posted on

SDT Holdings Engage SENECA Engineering for its Battery Project in Quebec

MONTREAL, QC / ACCESSWIRE / February 26, 2018 / SDT Holdings, Inc. / Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the “Company”).

The Company announced that it has contracted since December 2017, SENECA, an engineering consulting firm to help engineer and design the planned research battery factory announced by SDET earlier this month.

“Plans for the project are finalized, and the selection of SENECA as the project’s contractor is an essential first step to beginning the project. With their strong industry experience knowledge of the industrial process, requirements for rechargeable batteries and scalability, SENECA is an ideal partner to bring the project to terms,” stated Ramy Kamaneh, CEO of SDT Holdings, Inc.

“We are honored that SDET has chosen SENECA to assist them in this current project,” said Raymond Simoneau Ing. P.Eng., MBA, Partner, and Vice-President. “SENECA Engineering now employs over 75 experts which have helped realize thousands of industrial projects in some 15 countries, ranging from the smallest changes to an existing plant to the construction of entire commercial plants. We are excited to be working alongside SDET as their EPCM (“Engineering, Procurement, and Construction Management”) firm on this important project.” Our project teams have been and currently involved in the following innovation-related projects related to the rechargeable batteries:

  • LFP (lithium iron phosphate) cathode material
  • Hard Rock Spodumene Lithium Salts Conversion demonstration plant (battery grade)
  • Synthetic graphene plant (for the Li-ion battery anode)
  • High Purity Graphite anode material for the rechargeable battery.
  • LMP (lithium metal polymer) process design and plant development

Seneca is a private engineering consulting firm specializing in industrial materials process engineering. We offer comprehensive professional services for the implementation of industrial investment projects in Quebec and abroad. Our proven methods help you carry out and maintain full control of your boldest industrial investment projects. Our team of over 75 experts has helped realize thousands of industrial projects in some 15 countries, ranging from the smallest changes to an existing plant to the construction of entire commercial plants in EPCM mode. We particularly excel in executing projects that require the development of new processes or the integration of new technologies into existing processes aiming to reduce both OPEX and CAPEX.We act as the path from your ideas created in the laboratory, to the pilot plant and demonstration plant, finally leading to their fully operational commercial plants. Our project teams have been and currently involved in the following innovation-related projects related to the rechargeable batteries:

For more information about SENECA Engineering, visit us at www.seneca.ca/en/

Strategic Development of Electrification Technology (SDET) is a Quebec-based enterprise that specializes in the research and development, prototyping, benchmarking and piloting of industrial batteries. The company also produces low-cost, high-performance battery cells designed for a wide-range of heavy-duty industrial electric equipment. These cells are known to have exceptional autonomy and ultra-rapid recharge capabilities, without any degradation or loss of lifecycle.

SDT Holdings, Inc. is a Montreal-based industrial technology holding company that focuses on the development, production, and commercialization of its four subsidiaries, specializing in these areas: mining electrification, cryptocurrencies / blockchain, industrial batteries, internet of things and artificial intelligence for the industrial market. Dedicated to supplying quality, innovative technologies and battery solutions, SDT Holdings services the transport, mining, agricultural, industrial and earthmoving industries.

SDT Holdings, Inc

Publicly traded company (OTC PINK: WUHN)
Website: www.sdtholdings.com

For further information contact:

Phone: (514) 928-7368
E-mail: info@sdtholdings.com

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group (China), Inc.

Posted on

The Company announces that it has finalized the merger with Wuhan General Group (China), Inc. as part of a Reverse Take-Over or “RTO”

MONTREAL, Quebec, Feb. 22, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — SDT Holdings, Inc. / Wuhan General Group (China), Inc. (USOTC PINK:WUHN) (the “Company”).

The Company is proud to have reached this important milestone and believes that the RTO will provide our business with major opportunities in the international marketplace, access to long-term investors as well as growth capital. Thus, offering current and prospective investors a great investment opportunity.

The newly-merged company will assume the name SDT Holdings, Inc and has initiated the process to provide current filings and disclosures.

About

SDT Holdings, Inc. is a Montreal-based industrial technology holding company that focuses on the development, production and commercialization of its four subsidiaries, specializing in these areas: mining electrification, cryptocurrencies / blockchain, industrial batteries, internet of things and artificial intelligence for the industrial market. Dedicated to supplying quality, innovative technologies and battery solutions, SDT Holdings services the transport, mining, agricultural, industrial and earthmoving industries.

SDT Holdings, Inc

Publicly traded company (USAOTC Pink: WUHN)
Website: www.sdtholdings.com
For further information contact:
Phone: (514) 928-7368
E-mail: info@sdtholdings.com

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

 

Primary Logo

Posted on

Nova Scotians living with Advanced Parkinson’s Disease now have public access to DUODOPA® to manage their disease

  • Nova Scotia joins Alberta, Ontario, Quebec, Manitoba, British Columbia, and Yukon to offer DUODOPA

 

MONTREAL, QC, February 22, 2018 – AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that Canadians diagnosed with advanced Parkinson’s Disease living in Nova Scotia now have public access to DUODOPA. Parkinson’s disease is a progressive degenerative brain disorder with no cure.

 

DUODOPA is used to treat patients with advanced Parkinson’s disease who have severe and disabling motor symptoms that cannot be well controlled with available oral treatments. It is a levodopa and carbidopa medication combination delivered in the form of a gel through an intestinal pump.

 

Ryan Underhill, Managing Director for Parkinson Canada in Nova Scotia said, “We hear from people with Parkinson’s and their families every day. Having public access to effective treatment options gives them a sense of hope. We see firsthand how very challenging this disease is for individuals managing their unique symptoms through all stages of disease progression.”

 

Over 25 people are diagnosed with Parkinson’s every day in Canada1. Between 2011 – 2031, the number of Canadians diagnosed with Parkinson’s is expected to double to more than 163,7002.

Stéphane Lassignardie, General Manager of AbbVie Canada added, “We are thrilled that Nova Scotians now have access to DUODOPA. We continue to work with the healthcare community and the government to bring our medications to different communities. Our mission is to continue to advance scientific innovation in therapeutic areas where there are limited or no treatment options available to patients.”

 

About DUODOPA

 

DUODOPA® (levodopa/carbidopa intestinal gel) is a gel containing two medications delivered directly into the small intestine that is used to treat patients with advanced Parkinson’s disease who are responsive to levodopa treatment. DUODOPA is for use in patients who have severe and disabling motor symptoms of Parkinson’s disease that cannot be well controlled with available combinations of medications for Parkinson’s disease and for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopy gastrostomy- jejunostomy (PEG-J) tube required for administration. The symptoms of Parkinson’s disease include tremor, feeling rigid, slow movements, and balance problems.

 

DUODOPA® was approved in recognition of a high unmet need for effective therapies and no satisfactory alternatives. DUODOPA is approved in 34 countries and is used by more than 8,500 patients worldwide. Any medicines can have side effects. Like all medicines, DUODOPA® or the procedure of the PEG-J tube can cause serious side effects. DUODOPA® is contraindicated in patients with narrow-angle glaucoma, severe liver and renal insufficiency, severe heart failure, severe cardiac arrhythmia, suspicious, undiagnosed skin lesions or a history of melanoma, acute stroke and in patients taking non- selective MAO inhibitors and selective MAO type A inhibitors. DUODOPA® is also contraindicated in patients with clinical or laboratory evidence of uncompensated cardiovascular, cerebrovascular, endocrine, hematologic or pulmonary disease (including bronchial asthma).

 

For further information, please consult the DUODOPA Product Monograph at www.abbvie.ca

 

About AbbVie Care

The AbbVie Care program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment journey. For more information, consult www.abbviecare.ca.

 

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

###

 

Media:

Eileen Murphy AbbVie Canada (514) 832-7788

eileen.murphy@abbvie.com

 

 

1 Neurological Health Charities Canada (NHCC), Health Canada, Public Health Agency of Canada (PHAC), Canadian Institute of Health Research (CIHR). MAPPING CONNECTIONS: An Understanding of Neurological Conditions in Canada. Sept. 2014. pg.66.

2 POHEM-Neurological, Statistics Canada and Public Health Agency of Canada. Table 3-5: Projected prevalence, by select neurological condition, Canada, 2011, 2016, 2021, 2026, and 2031, Microsimulation Project. Ibid.,

Posted on

Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease

  • Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin disease
  • HUMIRA® (Adalimumab) is the first and only Health Canada-approved therapy for the treatment of adults living with
  • HUMIRA® (adalimumab) now reimbursed for HS in Manitoba, Saskatchewan, New Brunswick and Ontario

 

MONTREAL, QC, February 21, 2018 – AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that Canadians diagnosed with hidradentis suppurativea (HS) living in Manitoba, Saskatchewan, New Brunswick and Ontario now have public access to HUMIRA® (adalimumab).

 

HS is a chronic, systemic, immune-mediated skin disease which affects between 1 to 3% of the global population however the diagnosis is often delayed or the condition is misdiagnosed with the true prevalence unknown.1 HS is known to produce lesions in the skin that are inflamed (swollen), recurrent and chronic (lasting for an extended period of time). HS can have both a psychological and physical impact.

 

In general, HS has a greater impact on the quality of life of affected individuals compared to other dermatological conditions. 2 The average Canadian HS patient will see five doctors with over 17 visits spanning eight years before being diagnosed. HS is associated with intense pain, decreased mobility, and the deep-seated lesions (nodules or abscesses) may be accompanied by unpleasant odor and purulent drainage. The lesions are present under the arms, groin, and perianal area with the breasts being affected in female individuals. With time, healed lesions form scars which are sometimes extensive.3

 

Dr Afsaneh Alavi, dermatologist and Founder and past President of the Canadian Hidradenitis Suppurativa Foundation said, “We applaud the decisions of Manitoba, Saskatchewan, New Brunswick and Ontario to cover the first and only Health Canada approved treatment option for people living with HS. Having seen first-hand how HS impacts every aspect of a person’s life; nobody should have to endure this painful disease when effective treatment is available.”

 

“This is great news for HS patients living in Manitoba, Saskatchewan, New Brunswick and Ontario,” says Kathryn Andrews-Clay, Executive Director of the Canadian Skin Patient Alliance. “Our recent report on the lived experiences of HS patients highlights the need for an effective treatment to help improve their quality of life. We hope that the rest of the country will quickly follow Manitoba, Saskatchewan and Ontario’s leadership.”

 

Stéphane Lassignardie, General Manager of AbbVie Canada added, “We are motivated and encouraged for people living with HS in Manitoba, Saskatchewan, New Brunswick and Ontario. Enabling access to a much needed medication is extremely important for AbbVie in our mission to treat unmet medical needs. We are committed to partnering with payers across our country to ensure every Canadian with HS has equal access to our medication. “

 

 

About HUMIRA

 

HUMIRA resembles antibodies normally found in the body. It works by blocking TNF-α, a protein that, when produced in excess, plays a central role in the inflammatory responses of many immune-mediated diseases.

 

HUMIRA is one of the most comprehensively studied biologics available. The overall clinical database for HUMIRA spans 20 years across 14 indications globally (10 in Canada), including more than 100 clinical trials with more than 33,000 patients. HUMIRA is approved in 90 countries and used by more than 1 million patients worldwide.

 

1
1

Any medicines can have side effects. Like all medicines that affect the immune system, HUMIRA can cause serious side effects. Before initiation of, during and after treatment with HUMIRA, patients should be evaluated for active or inactive tuberculosis infection with a tuberculin skin test. For further information, please see the HUMIRA Product Monograph available at www.abbvie.ca.

 

About AbbVie Care

The AbbVie Care program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment journey. For more information, consult www.abbviecare.ca.

 

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 

Important Safety Information4

 

HUMIRA is a TNF blocker medicine that affects the immune system and can lower the body’s ability to fight infections. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. People should be tested for TB before HUMIRA use and monitored for signs and symptoms of TB during therapy. People at risk of TB may be treated with medicine for TB before starting HUMIRA. Treatment with HUMIRA should not be

 

started in a person with an active infection, unless approved by a doctor. HUMIRA should be stopped if a person develops a serious infection. People should tell their doctor if they live in or have been to a region where certain fungal infections are common, have had TB or hepatitis B, are prone to infections, or have symptoms such as fever, fatigue, cough, or sores.

 

For people taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers, including HUMIRA, the chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life- threatening if treated.

 

Other possible serious side effects with HUMIRA include hepatitis B infection in carriers of the virus; allergic reactions; nervous system problems; blood problems; certain immune reactions, including a lupus-like syndrome; liver problems; and new or worsening heart failure or psoriasis. The use of HUMIRA with other biologics DMARDS (e.g. anakinra or abatacept) or other TNF antagonists is not recommended. People using HUMIRA should not receive live vaccines.

 

Common side effects of HUMIRA include injection site reactions (redness, swelling, itching, pain or bruising), cough and cold symptoms, headache, rash, nausea, pneumonia, fever and abdominal pain.

 

HUMIRA is given by injection under the skin.

 

The benefits and risks of HUMIRA should be carefully considered before starting therapy.

 

This is not a complete list of the Important Safety Information for HUMIRA. For additional important safety information, please consult the HUMIRA Product Monograph1 at www.abbvie.ca

 

 

References

 

1 The Canadian Hidradenitis Suppurativa Foundation – www.hs-foundationcanada.org

2 Wolkenstein P, et al. J Am Acad Dermatol. 2007;56(4):621-623.

3 The Canadian Hidradenitis Suppurativa Foundation – www.hs-foundationcanada.org

4 HUMIRA (adalimumab) Product Monograph. AbbVie Corporation. (December 5, 2017).

 

 

###

 

Media:

Eileen Murphy AbbVie Canada (514) 832-7788

eileen.murphy@abbvie.com

Posted on

SDBT, Subsidiary of SDT Holdings, Builds a $10 Million Cryptocurrency Mining Facility in Quebec

MONTREAL, Feb. 08, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire —  SDT Holdings, Inc. / Wuhan General Group (China), Inc. (OTC PINK:WUHN) (the “Company”). The Company announces today that its subsidiary SDBT will start building a $10 Million Cryptocurrency Mining Facility North of Quebec region.

“This is an exciting time for our enterprise from an investment standpoint as big Chinese miners like Bitmain are turning to Quebec because of low energy cost and cold climate. This is obviously going to revolutionize our way of thinking about currency,” stated Ramy Kamaneh, CEO of SDT Holdings, Inc.
Link https://news.bitcoin.com/big-chinese-bitcoin-miners-are-turning-to-canada/

“We are currently securing a scalable up to 100 000 sq. ft warehouse with 30MW of available power which will provide the space and electricity for future expansion. We are currently in discussion with key hardware providers and joint ventures in the project,” stated Ramy Kamaneh, CEO of SDT Holdings, Inc.

About SDBT

Strategic Development of Blockchain Technology (SDBT) is a Quebec-based enterprise that focuses on large-scale mining cryptocurrencies farm in its region while offering other related services as well as the development of industrial blockchain technologies with the purpose of facilitating its access and adoption.

About SDT Holdings

SDT Holdings, Inc. is a Montreal-based industrial technology holding company that focuses on the development, production and commercialization of its four subsidiaries, specialized in these areas: mining electrification, cryptocurrencies / blockchain, industrial batteries, internet of things and artificial intelligence for the industrial market. Dedicated to supplying quality, innovative technologies and battery solutions, SDT Holdings services the transport, mining, agricultural, industrial and earthmoving industries.

SDT Holdings, Inc
Publicly traded company (OTC Pink:WUHN)
Website: www.sdtholdings.com
For further information contact:
Phone: (514) 928-7368
E-mail: info@sdtholdings.com

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

 

Primary Logo